alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.3112 C.I. Vat Orange 1. ( a ) *Identity.* The color additive is C.I. Vat Orange 1, Colour Index No. 59105.
( b ) *Uses and restrictions.* ( 1 ) The substance listed in paragraph (a) of this section may be used as a color additive in contact lenses in amounts not to exceed the minimum reasonably required to accomplish the intended coloring effect.
( 2 ) Authorization for this use shall not be construed as waiving any of the requirements of sections 510(k), 515, and 520(g) of the Federal Food, Drug, and Cosmetic Act (the act) with respect to the contact lens in which the color additive is used. A person intending to introduce a device containing C.I. Vat Orange 1 into commerce shall submit to the Food and Drug Administration either a premarket notification in accordance with subpart E of part 807 of this chapter, if the device is not subject to premarket approval, or submit and receive approval of an original or supplemental premarket approval application if the device is subject to premarket approval.
( c ) *Labeling.* The label of the color additive shall conform to the requirements of § 70.25 of this chapter.
( d ) *Exemption from certification.* Certification of this color additive is not necessary for the protection of the public health, and therefore the color additive is exempt from the certification requirements of section 721(c) of the act.
[50 FR 20407, May 16, 1985]
§ 522.814 Eprinomectin. ( a ) *Specifications.* Each milliliter of solution contains 50 milligrams (mg) eprinomectin.
( b ) *Sponsor.* See No. 000010 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See §§ 500.1410 and 556.227 of this chapter.
( d ) *Conditions of use in cattle on pasture* — ( 1 ) *Amount.* Administer 1 mg/kilogram of body weight by subcutaneous injection.
( 2 ) *Indications for use.* For the treatment and control of the following internal and external parasites: Gastrointestinal roundworms (adults and fourth-stage larvae) *Bunostomum phlebotomum, Cooperia oncophora,* *C. punctata, C. surnabada,* *Trichostrongylus axei, Ostertagia ostertagi* (including inhibited stage); (adults) *Haemonchus placei, Oesophagostomum radiatum,* *O. lyrata, T. colubriformis;* lungworms (adults) *Dictyocaulus viviparus;* cattle grubs *Hypoderma bovis;* mites *Sarcoptes scabiei* var. *bovis.* Prevents reinfection with *C. oncophora, C. punctata,* and *T. axei* for 100 days following treatment; *H. placei, O. radiatum,* *O. lyrata,* and *O. ostertagi* for 120 days following treatment; and *B. phlebotomum* and *D. viviparus* for 150 days following treatment.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian. Animals intended for human consumption must not be slaughtered within 48 days of the last treatment. This drug product is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established for pre-ruminating calves. Do not use in calves to be processed for veal.
[76 FR 72618, Nov. 25, 2011, as amended at 79 FR 37620, July 2, 2014; 84 FR 39184, Aug. 9, 2019]
---

EXHIBIT 13.B





CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with Amendment No. 2 to the Annual Report of Petaquilla Minerals Ltd. (the Company) on Form 20-F for the transition period ended May 31, 2008 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Bassam Moubarak, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:



1.

The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and



2.

The information contained in the Report fairly presents, in all materials respects, the financial condition and results of operations of the Company.





|                              | 
|----------------------------- | 
|/s/ Julie van Baarsen         | 
|Julie van Baarsen            
|(principal financial officer)



Dated:  January 28, 2010





The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.





---
Exhibit 32.1  FIRST
MARINER BANCORP
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002  Pursuant to, and for
purposes only of, 18 U.S.C. § 1350, I, Edwin F. Hale, Sr., Chief
Executive Officer of First Mariner Bancorp (the Company) hereby certify that (i) the
Annual Report of the Company on Form 10-K for the year ended December 31,
2008 filed with the Securities and Exchange Commission (the Report) fully
complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, and (ii) information contained in the
Report fairly presents, in all material respects, the financial condition and
results of operations of the Company.   Dated: March 31,
  2009
  /s/ Edwin F. Hale, Sr.Edwin F. Hale, Sr.Chief Executive Officer
# C_2014184EN.01004301.xml

| 16.6.2014 | EN | Official Journal of the European Union | C 184/43 |
| --- | --- | --- | --- |

16.6.2014

EN

Official Journal of the European Union

C 184/43

---

Action brought on 24 March 2014 — ZZ v FRA

(Case F-25/14)

2014/C 184/71

Language of the case: English

Parties

Parties

Applicant: ZZ (represented by: L. Levi and M. Vandenbussche, lawyers)

Applicant:

Defendant: European Union Agency for Fundamental Rights (FRA)

Defendant:

Subject-matter and description of the proceedings

Subject-matter and description of the proceedings

The annulment of the decision to terminate the indefinite duration contract of the Applicant, of the decision rejecting the complaint and to grant compensation for the moral and material damages suffered.

Form of order sought

Form of order sought

| — | Annul the decision of the FRA Director dated 13 June 2013 to terminate indefinite duration contract of the Applicant; |
| --- | --- |

—

Annul the decision of the FRA Director dated 13 June 2013 to terminate indefinite duration contract of the Applicant;

| — | annul the decision of the FRA Director dated 20 December 2013, rejecting the complaint; |
| --- | --- |

—

annul the decision of the FRA Director dated 20 December 2013, rejecting the complaint;

| — | grant the Applicant compensation for his material prejudice consisting of the difference between, on the one hand, the unemployment allowance which he will perceive from April 2014 and, after that, any potential replacement income or lack thereof and, on the other hand, his full salary, including all allowances, of 7 850,33 euros until the date of his full reintegration within the Agency (plus interest for late payment at the rate of 3 points above the European Central Bank rate); |
| --- | --- |

—

grant the Applicant compensation for his material prejudice consisting of the difference between, on the one hand, the unemployment allowance which he will perceive from April 2014 and, after that, any potential replacement income or lack thereof and, on the other hand, his full salary, including all allowances, of 7 850,33 euros until the date of his full reintegration within the Agency (plus interest for late payment at the rate of 3 points above the European Central Bank rate);

| — | grant the Applicant adequate compensation for the moral damage caused by the decision, which cannot be repaired by the annulment of the decision. This moral damage is assessed ex aequo et bono at 50 000,00 euros; |
| --- | --- |

—

grant the Applicant adequate compensation for the moral damage caused by the decision, which cannot be repaired by the annulment of the decision. This moral damage is assessed ex aequo et bono at 50 000,00 euros;

| — | order the Defendant to pay all costs. |
| --- | --- |

—

order the Defendant to pay all costs.

---
I 

118TH CONGRESS 

2D SESSION H. R. 7614 

To prohibit the payment of the salaries of the President and members of 

the cabinet if the President fails to submit the annual budget to Congress 

before the first Monday in February of any year, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 11, 2024 

Ms. MACE introduced the following bill; which was referred to the Committee 

on Oversight and Accountability 

A BILL 

To prohibit the payment of the salaries of the President 

and members of the cabinet if the President fails to 

submit the annual budget to Congress before the first 

Monday in February of any year, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Presidential Budget 

5 Accountability Act’’. 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7614 IH

1 SEC. 2. PROHIBITION ON PAY FOR PRESIDENT AND SENIOR 

2 EXECUTIVE BRANCH OFFICIALS IF PRESI3 DENT’S BUDGET NOT SUBMITTED ON TIME. 

4 (a) PROHIBITION.—Notwithstanding any other provi5 sion of law, if the President does not submit to Congress 

6 the budget for any fiscal year on or before the first Mon7 day in February of any calendar year as required under 

8 section 1105(a) of title 31, United States Code, during 

9 the period described in subsection (b)(2) the President and 

10 any senior official may not receive any pay. In this sub11 section, the term ‘‘senior official’’ means any member of 

12 the President’s cabinet. 

13 (b) ESCROW FOR PRESIDENTIAL PAY.— 

14 (1) IN GENERAL.—In order to ensure that this 

15 section is carried out in a manner that shall not 

16 vary the compensation of the President in violation 

17 of clause 7 of section 1 of article II of the Constitu18 tion of the United States, if by the first Monday in 

19 February of any calendar year the President has not 

20 submitted the annual budget for the fiscal year be21 ginning on October 1 of that year as required under 

22 such section 1105(a), during the period described in 

23 paragraph (2) the appropriate payroll administrator 

24 shall deposit in an escrow account all payments oth25 erwise required to be made during such period for 

26 the compensation of the President, and shall release 


ssavage on LAPJG3WLY3PROD with BILLS
3 

•HR 7614 IH

1 such payments to the President upon the expiration 

2 of such period. 

3 (2) PERIOD DESCRIBED.—The period described 

4 in this paragraph is the period which begins on Feb5 ruary 6 of such calendar year and ending on May 

6 6 of such calendar year. 

7 (c) APPLICATION.—This Act shall apply with respect 

8 to the President’s annual budget submission under such 

9 section 1105(a) for fiscal year 2025 and each fiscal year 

10 thereafter. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
§ 808.35 Revocation of an exemption. ( a ) An exemption from preemption pursuant to a regulation under this part shall remain effective until the Commissioner revokes such exemption.
( b ) The Commissioner may by regulation, in accordance with § 808.25, revoke an exemption from preemption for any of the following reasons: ( 1 ) An exemption may be revoked upon the effective date of a newly established requirement under the Federal Food, Drug, and Cosmetic Act which, in the Commissioner's view, addresses the objectives of an exempt requirement and which is described, when issued, as preempting a previously exempt State or local requirement.
( 2 ) An exemption may be revoked upon a finding that there has occurred a change in the bases listed in § 808.20(c)(4) upon which the exemption was granted.
( 3 ) An exemption may be revoked if it is determined that a condition placed on the exemption by the regulation under which the exemption was granted has not been met or is no longer being met.
( 4 ) An exemption may be revoked if a State or local jurisdiction fails to submit records as provided in § 808.20(c)(6).
( 5 ) An exemption may be revoked if a State or local jurisdiction to whom the exemption was originally granted requests revocation.
( 6 ) An exemption may be revoked if it is determined that it is no longer in the best interests of the public health to continue the exemption.
( c ) An exemption that has been revoked may be reinstated, upon request from the State or political subdivision, if the Commissioner, in accordance with the procedures in § 808.25, determines that the grounds for revocation are no longer applicable except that the Commissioner may permit abbreviated submissions of the documents and materials normally required for an application for exemption under § 808.20.
[43 FR 18665, May 2, 1978, as amended at 87 FR 50761, Aug. 17, 2022]
Exhibit



Exhibit 10.2.1.2















AMENDMENT 
TO THE CONSOLIDATED EDISON 
COMPANY OF NEW YORK, INC. 
SUPPLEMENTAL RETIREMENT INCOME PLAN


As Amended and Restated Effective January 1, 2009




























































Exhibit 10.2.1.2





Pursuant to resolutions adopted by the Board of Directors of Consolidated Edison Company of New York, Inc. (“CECONY”), the Board of Directors of Consolidated Edison, Inc. (“CEI”), the Board of Directors of Orange and Rockland Utilities, Inc. (“O&R”) and the Board of Directors of Con Edison Transmission, Inc.(“CET”), at a meeting duly held on November 17, 2016, the undersigned hereby approves the following amendments to the Consolidated Edison Company of New York, Inc. Supplemental Retirement Income Plan, (the “Plan”) effective January 1, 2017.


		
	1.
	The “Purpose” section of the Plan is amended by adding to the following to the end thereof:  




“Effective on and after January 1, 2017, participation in the Plan is frozen.  Participation is limited solely to Eligible Employees who are Participants on or before December 31, 2016.”


		
	2.
	Section 1.29 “Eligible Employee” is amended by adding the following to the end thereof:




“Notwithstanding the foregoing, any officer or employee hired by the Company or a Participating Company on or after January 1, 2017, shall not qualify as an Eligible Employee and shall not participate in the Plan.”


		
	3.
	A new Section 1.44 “Pension Choice” is added as follows: 




“Pension Choice” shall have the meaning set forth in the Retirement Plan.”




		
	4.
	Section 2.01 is amended by adding the following to the end thereof:




“Effective June 1, 2017, a Cash Balance Formula Participant who makes a Pension Choice under the Retirement Plan to transfer, on a prospective basis, to coverage under the Defined Contribution Pension Formula in the Thrift Savings Plan shall, effective as of the date of the transfer, cease to accrue additional compensation credits under this Plan.”


		
	5.
	Section 2.06 is amended by adding the following to the end thereof:  




Beginning on or after January 1, 2017, each Eligible Employee who is reemployed by the Company or an Affiliated Company after a Separation from Service, and who began to receive, or received some or all of her or his Benefit, including his or her Retirement Allowance payable under the Retirement Plan, will not be eligible to participate in this Plan.  




Except as hereby amended, all of the terms and conditions set forth in the Plan shall remain in full force and effect.  




















Exhibit 10.2.1.2





IN WITNESS WHEREOF, the undersigned has executed this instrument this 2nd day of 
May 2017. 


 
CONSOLIDATED EDISON COMPANY OF NEW YORK, INC.




/s/ Susan Carson 
Director of Compensation
United States Court of Appeals

For the First Circuit

No. 06-2151

VERIZON NEW ENGLAND, INC.,

Plaintiff, Appellant,

v.

MAINE PUBLIC UTILITIES COMMISSION; STEPHEN L. DIAMOND, in his

official capacity as Commissioner of the Maine Public Utilities

Commission; SHARON M. REISHUS, in her official capacity as

Commissioner of the Maine Public Utilities Commission; KURT W.

ADAMS, in his official capacity as Commissioner of the Maine

Public Utilities Commission,

Defendants, Appellees.

ERRATA

The opinion of this court issued on September 6, 2007, is

amended as follows:

On page 11, line 18, replace the words "present on a legal"

with the words with "present a legal".
# C_2015034EN.01005301.xml

| 2.2.2015 | EN | Official Journal of the European Union | C 34/53 |
| --- | --- | --- | --- |

2.2.2015

EN

Official Journal of the European Union

C 34/53

---

Action brought on 18 November 2014 — ZZ v Commission

(Case F-134/14)

(2015/C 034/65)

Language of the case: French

Parties

Parties

Applicant: ZZ (represented by: S. Rodrigues, A. Tymen, lawyers)

Applicant:

Defendant: Commission

Defendant:

Subject-matter and description of the proceedings

Subject-matter and description of the proceedings

The annulment of the Commission’s decision to exclude the existence of harm arising from the delay taken by the Commission to establish the occupational origin of the applicant’s sickness and to pay her only the amount of EUR 2  000 as compensation for the uncertainty as regards recognition of the occupational origin of her illness and the claim for damages for the non-material harm allegedly suffered.

Form of order sought

Form of order sought

| — | Annul the decision of the European Commission of 8 August 2014, received by registered post on 1 October 2014 by the applicant, rejecting her complaint of 24 April 2014; |
| --- | --- |

—

Annul the decision of the European Commission of 8 August 2014, received by registered post on 1 October 2014 by the applicant, rejecting her complaint of 24 April 2014;

| — | As far as necessary, annul the decision of the European Commission of 3 February 2014, which only partially granted the applicant’s request for compensation of 16 October 2013; |
| --- | --- |

—

As far as necessary, annul the decision of the European Commission of 3 February 2014, which only partially granted the applicant’s request for compensation of 16 October 2013;

| — | Order compensation for the non-material harm assessed ex aequo et bono at EUR 20  000; |
| --- | --- |

—

Order compensation for the non-material harm assessed ex aequo et bono at EUR 20  000;

| — | Order the Commission to pay the entire costs. |
| --- | --- |

—

Order the Commission to pay the entire costs.

---
EX-10.17(b)



 Exhibit 10.17(b) 

First Amendment to the Frontier Airlines, Inc Credit Card Affinity Agreement 

This First Amendment to the Frontier Airlines Credit Card Affinity Agreement, made this 12th day of March 2003 by and between Juniper Bank
(“Juniper”) and Frontier Airlines, Inc (“Frontier”), amends the Frontier Airlines Credit Card Agreement between the parties dated March 12, 2003 (the “Agreement”). 

RECITALS: 
 The parties
desire to clarify the manner in which the Credit Card Program is administered. 
 THEREFORE, the parties agree as follows: 

 

	 	1.	FRONTIER agrees to assign a full-time Marketing Coordinator to administer the Co-Branded Credit Card Program (job description attached hereto as Exhibit 1) hereinafter the
“Program Administrator”). 

  

	 	2.	JUNIPER shall pay Frontier monthly as provided on Exhibit 2 hereto, to offset FRONTIER’s expense associated with the Program Administrator, provided that in any month that the Program Administrator position is
unfilled for more than *****, JUNIPER shall have no obligation to pay FRONTIER for that month(s). FRONTIER will invoice JUNIPER on a *****. 

  

	 	3.	All other terms and conditions of the Agreement shall remain in effect except as expressly modified herein or in another writing signed by both parties. Capitalized terms shall have the same meaning as set forth in the
Agreement. 

  

	 	4.	This Amendment shall be governed by and construed under the laws of the State of Delaware as applied to agreements among Delaware residents entered into and to be performed entirely within the State of Delaware.


  

	 	5.	This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 


Intending to be legally bound, the parties have executed this Amendment as of the date set forth above. 

 

							
	JUNIPER BANK	  		 	FRONTIER AIRLINES, INC.	 	
				
	 /s/ [Authorized Signatory]
	  		 	 /s/ Howard Diamond
	 	
	(Signature)	  		 	(Signature)	 	
				
	 [Authorized Signatory]
	  		 	 SVP, General Counsel & Secretary
	 	
	(Title)	  		 	(Title)	 	
				
	 March 12, 2003
	  		 	 March 12, 2003
	 	
	(Date)	  		 	(Date)	 	


  

	*****	Confidential portions of the material have been omitted and filed separately with the Securities and Exchange Commission. 



  
 1 








 EXHIBIT 1 

Job Description 

  

					
	PAGE 2	 		  	
	*****	 		  	PROCESSING SERVICES AGREEMENT
		 	JUNIPER FINANCIAL CORP.	  	
	This document is confidential and proprietary and may not be distributed outside of Juniper Financial Crop. Or e-PROFILE,
Inc.









 EXHIBIT 2 

Payment Schedule 
 ***** 

  

	*****	Confidential portions of the material have been omitted and filed separately with the Securities and Exchange Commission. 



  
 3
§ 520.2240b Sulfaethoxypyridazine tablets. ( a ) *Specifications.* ( 1 ) Each tablet contains 2.5 or 15 grams sulfaethoxypyridazine.
( 2 ) Each extended-release tablet contains 5 grams sulfaethoxypyridazine.
( b ) *Sponsor.* See No. 054771 § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.650 of this chapter.
( d ) *Conditions of use in cattle* — ( 1 ) *2.5- or 15-gram tablets* — ( i ) *Amount.* Administer 25 milligrams per pound of body weight per day for 4 days. Use as the sole source of sulfonamide.
( ii ) *Indications for use.* For treatment of respiratory infections (pneumonia, shipping fever), foot rot, calf scours; as adjunctive therapy in septicemia accompanying mastitis and metritis.
( iii ) *Limitations.* Do not treat within 16 days of slaughter. Milk that has been taken from animals during treatment and for 72 hours (6 milkings) after latest treatment must not be used for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *15-gram extended-release tablets* — ( i ) *Amount.* Administer 100 milligrams per pound of body weight. Use as the sole source of sulfonamide.
( ii ) *Indications for use.* For treatment of foot rot and respiratory infections (shipping fever and pneumonia) caused by sulfonamide-susceptible pathogens (*E. coli, Streptococci,* *Staphylococci, Sphaerophorus necrophorus* and Gram-negative rods including *Pasteurella*); and for use prophylactically during periods of stress for reducing losses due to sulfonamide sensitive disease conditions.
( iii ) *Limitations.* Do not treat within 16 days of slaughter. Not for use in lactating dairy cows. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 28830, May 20, 2014]